Bayer, Novartis Near Settlement Over MS Drug
The companies jointly asked a court in California to postpone a deadline from Jan. 16 to Feb. 20 so they could continue settlement talks, the Financial Times Deutschland reported.
Currently, Bayer unit Schering and Novartis unit Chiron have a licensing deal over Betaseron set to end in 2008. Chiron exclusively produces the drug in the United States for Schering and receives a 22.5%...
To view the full article, register now.